Lysosomal Therapeutics, Inc. — Form D/A
Lysosomal Therapeutics, Inc. of CAMBRIDGE, MA, a company, filed a Form D amendment with the SEC on 2017-01-18. The offering totals $26.1M, of which $26.1M was reported sold. Industry: Biotechnology.
Offering
- Filed: 2017-01-18
- Form: D/A
- Accession: 0001607854-17-000001
- Industry: Biotechnology
- Exemptions: 06b
- Total offering: $26.1M
- Amount sold: $26.1M
- Investors: 9
- Date of first sale: 2015-01-30
- Security types: equity
- Revenue range: Decline to Disclose
- SEC file number: 021-233905
Issuer
- Name: Lysosomal Therapeutics, Inc.
- CIK: 0001607854
- Entity type: Corporation
- Jurisdiction: DELAWARE
- Incorporated: 2011
- Address: 19 BLACKSTONE STREET, CAMBRIDGE, MA, 02139
- Phone: 617-714-9620
Officers, directors & promoters (18)
| Name | Role | Location |
|---|
| Bruce Booth | Director | Cambridge, MA |
| Bernard Davitian | Director | Chicago, IL |
| Steven Hall | Director | Fort Worth, TX |
| Carole Neuchterlein | Director | South San Francisco, CA |
| Clay Thorp | Director | Durham, NC |
| Daniel Geffken | Executive Officer | Boston, MA |
| Peter Wirth | Director | Cambridge, MA |
| Robert Carpenter | Director | Vancouver, A1 |
| Robert Carpenter | Executive Officer | Vancouver, A1 |
| Carole Nuechterlein | Director | Chevy Chase, MD |
| Carole E Nuechterlein | Director | Cambridge, MA |
| Clay E Thorp | Director | Cambridge, MA |
| Cornelis Been | Director | Cambridge, MA |
| Cornelis Been | Executive Officer | Cambridge, MA |
| Steven E Hall | Director | Indianapolis, IN |
| Henri Termeer | Director | Cambridge, MA |
| Bruce L Booth | Director | Boulder, CO |
| Dimitri Krainc | Director | Cambridge, MA |
Other filings by this issuer (4)
More